FDA clears Cerecor’s FP01

Wednesday, April 11, 2012 04:04 PM

Baltimore-based biopharmaceutical company Cerecor’s Investigational New Drug (IND) application for FP01 for the treatment of cough has cleared the 30 day deliberation period by the FDA. 

The company plans to immediately characterize the pharmacokinetics of FP01 lozenges in humans and thereafter initiate an exploratory phase II acute cough study in healthy subjects with upper respiratory tract infections (URTI).

"The data we plan to generate from the initial phase II study will educate us about the effect size of FP01 as an antitussive, providing for future studies," said Blake Paterson, CEO and co-founder of Cerecor.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs